Cubist (CBST) PT Raised to $73 on Likely Approval of Tedizolid - Cantor
Tweet Send to a Friend
Cantor Fitzgerald maintained a Hold rating on Cubist Pharmaceuticals (NASDAQ: CBST) and raised its target to $73.00 (from $70.00). Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
